MedTrace Logo

Behavioral Effects of Pregabalin and Cannabis

NCT01511640 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-09-10

Study results available
· View outcomes & findings →

Summary

Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.

Conditions

  • Cannabis-use Disorders

Interventions

DRUG

Pregabalin

pregabalin 2x daily for duration of study

DRUG

Placebo

placebo 2x daily for duration of study

Sponsors & Collaborators

  • Joshua A. Lile, Ph.D.

    lead OTHER

Principal Investigators

  • Joshua A. Lile, Ph.D. · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-03-15
Completion
2020-03-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511640 on ClinicalTrials.gov